Basic Information
-
Brand Name: Cefakind-CV 500 Tablet
-
Type: Antibiotic (Cephalosporin + Beta-lactamase Inhibitor)
-
Form: Tablet
-
Pack Size: Strip of 6 / 10 tablets (commonly available)
-
Manufacturer / Marketer: Mankind Pharma Ltd.
Composition (per tablet)
-
Cefuroxime Axetil – 500 mg
-
Clavulanic Acid – 125 mg
Uses / Indications
Cefakind-CV 500 Tablet is prescribed for moderate to severe bacterial infections, including:
-
Respiratory tract infections: pneumonia, bronchitis, sinusitis, tonsillitis, pharyngitis
-
ENT infections – otitis media, sinus infections, throat infections
-
Urinary tract infections (UTI) – cystitis, pyelonephritis
-
Skin & soft tissue infections: cellulitis, abscesses, wound infections
-
Bone & joint infections
-
Post-operative infections
-
Mixed bacterial infections resistant to cephalosporins alone
Mechanism of Action
-
Cefuroxime (Cephalosporin antibiotic): Inhibits bacterial cell wall synthesis → causes bacterial lysis & death (bactericidal)
-
Clavulanic Acid (Beta-lactamase inhibitor): Blocks bacterial enzymes (beta-lactamases) that cause resistance → makes cefuroxime more effective
-
Combined Effect: Broad-spectrum activity, even against resistant bacteria
Dosage & Administration
-
Adults: 1 tablet twice daily, or as prescribed by doctor
-
Children (>12 years): Dose depends on body weight; pediatric suspensions preferred for younger children
-
Best taken after meals for better absorption
-
Duration: usually 7–14 days, depending on infection type
Side Effects
-
Common: nausea, diarrhea, stomach pain, headache
-
Rare: rash, dizziness, oral thrush, vaginal yeast infection
-
Severe (rare): allergic reactions, Clostridium difficile–associated diarrhea, liver enzyme changes
Precautions & Warnings
-
Use only on doctor’s prescription
-
Avoid if allergic to cephalosporins, penicillins, or clavulanic acid
-
Use cautiously in patients with liver or kidney impairment
-
May interact with anticoagulants (like warfarin)
-
Pregnant & breastfeeding women: safe if prescrib
Reviews
There are no reviews yet.